Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: A retrospective cohort study

Critical Care

Volumn 18, Issue 6, 2014, Pages

  Zilberberg, Marya D ^a,b   Shorr, Andrew F ^c   Micek, Scott T ^d   Vazquez Guillamet, Cristina ^e   Kollef, Marin H ^f  

^a EviMed Research Group LLC   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d ST LOUIS COLLEGE OF PHARMACY   (United States)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CIPROFLOXACIN; DAPTOMYCIN; FLUCONAZOLE; GENTAMICIN; IMIPENEM; LINEZOLID; MEROPENEM; MICAFUNGIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEROIDES; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CHARLSON COMORBIDITY INDEX; CITROBACTER FREUNDII; COHORT ANALYSIS; COMORBIDITY; DISEASE SEVERITY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE SEPSIS; HEALTHCARE ASSOCIATED INFECTION; HOSPITALIZATION; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SEPTIC SHOCK; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; PHYSIOLOGY; SEPSIS; SHOCK, SEPTIC; TRENDS;

AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEPSIS; SHOCK, SEPTIC;

EID: 84926343938     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-014-0596-8     Document Type: Article

References (29)

1. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008, 6:751-763. 10.1586/14787210.6.5.751, 18847410.
2. National Nosocomial Infections Surveillance (NNIS) system report.Am J Infect Control 2004, 32:470..
3. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004, 48:4606-4610. 10.1128/AAC.48.12.4606-4610.2004, 15561832.
4. Zilberberg MD, Shorr AF. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009. J Hosp Med 2013, 8:559-563. 24022878.
5. Zilberberg MD, Shorr AF. Secular trends in Gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009. Infect Control Hosp Epidemiol 2013, 34:940-946. 10.1086/671740, 23917908.
6. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009-2010. Infect Control Hosp Epidemiol 2013, 34:1-14. 10.1086/668770, 23221186.
7. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007, 51:3568-3573. 10.1128/AAC.00851-07, 17682100.
8. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002, 122:262-268. 10.1378/chest.122.1.262, 12114368.
9. Alvarez-Lerma F. ICU-acquired pneumonia study group: modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996, 22:387-394. 10.1007/BF01712153, 8796388.
10. Zilberberg MD, Shorr AF, Micek MT, Mody SH, Kollef MH. Antimicrobial therapy escalation and hospital mortality among patients with HCAP: a single center experience. Chest 2008, 134:963-968. 10.1378/chest.08-0842, 18641103.
11. Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH. Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med 2011, 39:46-51. 10.1097/CCM.0b013e3181fa41a7, 20890186.
12. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474. 10.1378/chest.115.2.462, 10027448.
13. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003, 31:2742-2751. 10.1097/01.CCM.0000098031.24329.10, 14668610.
14. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003, 115:529-535. 10.1016/j.amjmed.2003.07.005, 14599631.
15. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Pérez XL, Sirvent JM. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009, 180:861-866. 10.1164/rccm.200812-1912OC, 19696442.
16. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637. 10.1097/CCM.0b013e31827e83af, 23353941.
17. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
18. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004, 4:519-527. 10.1016/S1473-3099(04)01108-9, 15288826.
19. Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement. M100-S12 2002, National Committee for Clinical Laboratory Standards, Wayne, PA.
20. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement. M100-S17 2007, Wayne, PA, Clinical Laboratory Standards Institute.
21. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
22. Falagas M, Fragoulis K, Kasiakou S, Sermaidis G, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005, 26:504-507. 10.1016/j.ijantimicag.2005.09.004, 16280245.
23. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, Gregorakos L. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003, 7:R78-R83. 10.1186/cc2358, 12974973.
24. Falagas E, Kasiakou S. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006, 10:R27. 10.1186/cc3995, 16507149.
25. Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012, 54:670-680. 10.1093/cid/cir934, 22322268.
26. GAIN: How a New Law is Stimulating the Development of Antibiotics. []., http://www.pewhealth.org/other-resource/gain-how-a-new-law-is-stimulating-the-development-of-antibiotics-85899518481
27. Guidelines for the management of adults with hospital-acquired pneumonia, ventilator-associated pneumonia, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. 10.1164/rccm.200405-644ST.
28. O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph AG, Rupp ME, Saint S. Guidelines for prevention of intravascular catheter-related infections. Clin Infect Dis 2011, 52:1087-1099. 10.1093/cid/cir138, 21467014.
29. Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Clin Infect Dis 2007, 44:159-177. 10.1086/510393, 17173212.